A study showed that spebrutinib (CC-292), a small molecular inhibitor of Bruton’s tyrosine kinase (BTK), significantly reduces the serum concentration of CXCL13 and shows a therapeutic effect on rheumatoid arthritis [196]. Here, CXCL13 is linked to rheumatoid arthritis.